-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Immuno-Biology
-
Research Points to Translational Path Toward Precision Immunotherapies for EGFR-Mutant NSCLC
Dr. Yongfeng He said recent data show EGFR-L858R to be a shared, druggable neoantigen and provide a compelling rationale for the development of mutation-directed immunotherapies.
-
TKI Plus Checkpoint Inhibitor Without Chemotherapy Shows Promise as Initial Option in Advanced NSCLC
The combination of an anti-angiogenic tyrosine kinase inhibitor (TKI) and an anti-PD-1 immunotherapy proved promising, regardless of PD-L1 expression levels, as a first-line therapy for treatment-naïve patients with advanced NSCLC who did not harbor known driver gene mutations. In a small phase I trial combining the TKI anlotinib and the immunotherapy sintilimab, the overall response…
-
Co-mutations in DNA Damage-Response Pathways May Predict Effectiveness of Checkpoint Inhibitors in NSCLC
NSCLC that harbors more than one DNA damage-response (DDR) gene alteration is more likely to respond to immunotherapy than disease that harbors one or no such mutations. So concluded investigators who analyzed next-generation sequencing (NGS) of the circulating tumor DNA of patients with advanced NSCLC who had received the PD-L1 inhibitor atezolizumab or the chemotherapy…
-
Translating Early Research to Adapt CAR T-Cell Therapy to Solid Tumors
Although the initial research into adoptive T-cell therapy for solid tumors was related to tumor-infiltrating lymphocytes, there is a growing interest in the use of adoptive T-cell therapy for the treatment of these diseases. As part of Friday’s Plenary session “PL03: Bench to Bedside (Immunology),” Prasad S. Adusumilli, MD, FACS, attending and deputy chief of…